Anika Gupta is a principal at GV, focusing on life sciences investments.

Before GV, Anika obtained a Ph.D. in bioinformatics and genomics at Harvard University and the Broad Institute of Harvard and MIT, where she leveraged single-cell genomics and statistical genetics to understand the causal basis for diseases like autoimmunity with more precision. Her thesis work with Eric Lander and Soumya Raychaudhuri has been published in the journals Nature Genetics and Proceedings of the National Academy of Sciences.

Anika has helped build companies in cell therapy and oncology, and she has contributed to the bioinformatics pipelines for patient stratification at Foundation Medicine and for predicting promising combination immunotherapies at Merck.

Anika holds a B.S. in Computer Science and Molecular Biology from MIT, where she also discovered her zeal for data-driven biomedical innovation through early-stage biotechnology.